Results 101 to 110 of about 39,316 (219)

Determining cellular and biochemical function of a novel adhesion molecule in kidneys. [PDF]

, 2016
Acute kidney injury is an abrupt loss of kidney function that develops in short time with limited effective treatments other than kidney transplantation. We have identified TMIGD1 (Transmembrane immuno- globulin domain 1) as a novel receptor expressed in
Arafa, Emad
core   +1 more source

The Allium cepa Derived Compound Propyl Propane Thiosulfonate (PTSO) Improves Tumorigenesis Due to Its Immunomodulatory Effect: A Preclinical Study

Phytotherapy Research, EarlyView.
In vitro and in vivo effects of PTSO in colorectal cancer preclinical models, highlighting antiproliferative, pro‐apoptotic, barrier‐enhancing, antitumor, prebiotic and immunomodulatory properties. Created using BioRender. ABSTRACT Allium‐derived organosulfur compounds offer significant health benefits.
María Jesús Rodríguez‐Sojo, Laura Hidalgo‐García, Jose Alberto Molina‐Tijeras, Laura López‐Escanez, Luckman Gbati, Teresa Vezza, Patricia Diez‐Echave, Antonio Jesús Ruiz‐Malagón, Jorge García‐García, Federico García, Alberto Baños, Lidia Gil‐Martínez, Rocío López‐Posadas, Markus F. Neurath, Julio Gálvez, María Elena Rodríguez‐Cabezas, Alba Rodríguez‐Nogales   +16 more
wiley   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

PLoS ONE, 2013
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezomib-regulated cellular pathways. In the present study, we investigated CK2 expression in multiple myeloma and mantle cell lymphoma, two bortezomib ...
Sabrina Manni, Alessandra Brancalion, Elisa Mandato, Laura Quotti Tubi, Anna Colpo, Marco Pizzi, Rocco Cappellesso, Fortunato Zaffino, Speranza Antonia Di Maggio, Anna Cabrelle, Filippo Marino, Renato Zambello, Livio Trentin, Fausto Adami, Carmela Gurrieri, Gianpietro Semenzato, Francesco Piazza   +16 more
doaj   +1 more source

The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver [PDF]

, 2019
Secreted frizzled-related protein (sFRP) 4 is an adipokine with increased expression in white adipose tissue from obese subjects with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
Al-Hasani, Hadi, Barbosa, David, Fahlbusch, Pia, Herzfeld de Wiza, Daniella, Hörbelt, Tina, Knebel, Birgit, Kotzka, Jorg, Lapauw, Bruno, Müller-Wieland, Dirk, Ouwens, Margriet, Thoresen, G Hege, Van de Velde, Frederique, Van Nieuwenhove, Yves   +12 more
core   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment

Scientific Reports
Neuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment.
Kévin Berthenet, Eliézer Aïmontché, Sara El Mrini, Johan Brière, Nathalie Pion, Isabelle Iacono, Stéphanie Brejon, Karine Monier, Frédéric Catez, Gabriel Ichim, Valérie Combaret, Hichem C. Mertani, Jean-Jacques Diaz, Marie Alexandra Albaret   +13 more
doaj   +1 more source

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Haematologica, 2015
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone ...
Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt   +22 more
doaj   +1 more source

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, EarlyView.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Calcium Channel Blocker Verapamil Enhances Reticulum Stress and Death Induced by Proteasome Inhibition in Myeloma Cells

Neoplasia: An International Journal for Oncology Research, 2010
The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often develop secondary resistance to proteasome inhibitors.
Silke Meister, Benjamin Frey, Veronika R. Lang, Udo S. Gaipl, Georg Schett, Ursula Schlötzer-Schrehardt, Reinhard E. Voll   +6 more
doaj   +1 more source